1
November 2024
ProBiotix Health
plc
("ProBiotix" or the "Company" or, together with its
subsidiary, the "Group")
Result of Requisitioned
General Meeting - Resolutions Defeated
Result of Requisitioned
General Meeting
ProBiotix Health plc (AQSE: PBX),
the life sciences business developing probiotics to support
cardiometabolic health, is pleased to announce that at the
Requisitioned General Meeting held earlier today, all three
resolutions were duly defeated.
The proxy votes cast at the meeting
are summarised in the table below.
|
Resolution
|
For
|
Against
|
Total votes cast as % of
Issued Share Capital
|
Votes
Withheld
|
|
Number of
Votes
|
% of
votes cast
|
Number of
Votes
|
% of
votes cast
|
|
1. To remove
Steen Andersen as a Director of the Company.
|
18,869,846
|
29.74
|
44,536,597
|
70.20
|
40.09
|
37,977
|
|
2. To remove
Frederik Bruhn-Petersen as a Director of the Company.
|
18,962,488
|
29.89
|
44,443,955
|
70.05
|
40.09
|
37,977
|
|
3. To remove any person appointed to
the Board after the date of the notice*, as a Director of the
Company.
*being 24 September 2024, the date of the
Requisition.
|
18,866,796
|
29.74
|
44,538,399
|
70.20
|
40.09
|
39,225
|
The 'against' votes include those
giving discretion to the Chairman of the meeting. A
'vote withheld' is not a vote in law and is not counted in the
calculation of the votes 'for' or 'against' a
resolution.
The Independent Directors are very
grateful for the support received from Shareholders for their
opposition to the Requisition.
Comment from the Independent Directors
The Independent Directors are
angered by the false and inaccurate allegations made against the
Company and certain of its Directors over the last few weeks.
Whilst the Company and the relevant individuals reserve their
respective rights with respect to such allegations, the Independent
Directors believe that the Company should now draw a line under
this regrettable incident and re-focus efforts on the continued
growth of ProBiotix under the leadership of Steen
Andersen.
The Independent Directors have also
been deeply disappointed by the requisitioning of this General
Meeting, given the inevitable distraction it has caused at a
crucial time for the Company and the costs incurred in dealing with
the Requisition.
Adam Reynolds, Non-Executive
Chairman of ProBiotix Health plc commented: "We are delighted that these
unwelcome and unwarranted resolutions have been defeated. We now
look forward to constructive engagement with all the Company's
stakeholders, including Seneca, as we continue to build on the
strong momentum within our business.
"I would like to place on record our
thanks to our shareholders and Advisers, and to reiterate our
support for both Steen Andersen as our Chief Executive and Frederik
Bruhn-Petersen as our new Non-executive Director."
For
further information, please contact:
|
ProBiotix Health plc
|
https://probiotixhealth-ir.com/
|
|
Steen Andersen, Chief Executive
Officer
|
Contact via Walbrook
below
|
|
|
|
|
Peterhouse Capital Limited
(Aquis Corporate Adviser and
Broker)
|
|
|
Mark Anwyl
|
Tel: 020
7220 9793
|
|
|
|
|
Walbrook PR Ltd
|
probiotix@walbrookpr.com
|
|
Anna Dunphy
|
Mob: 07876
741 001
|
Notes:
(i)
Words and expressions defined in the circular to Shareholders dated
15 October 2024 have the same meaning in this
announcement.
(ii)
For the avoidance of doubt, references in this announcement to the
"Independent Directors" are to the Directors of ProBiotix other
than Stephen O'Hara, who is a Non-executive Director of the Company
and is also Chief Executive of OptiBiotix. As such, he has a
conflict of interest and has not been involved in the
considerations of the Independent Directors.
This announcement contains
information which, prior to its disclosure, was considered inside
information for the purposes of the UK Market Abuse Regulation and
the Directors of the Company are responsible for the release of
this announcement.